|
2022–2027 |
A double-blind, randomized, placebo-controlled clinical trial, investigating the effect and safety of oral semaglutide in people with early Alzheimer's disease (EVOKE) |
|
2022–2027 |
A double-blind, randomized, placebo-controlled clinical trial, investigating the effect and safety of oral semaglutide in people with early Alzheimer's disease (EVOKE-PLUS) |
|
2022–2023 |
Academic Teaching Experience Acquisition for Young PhD Scientists at Aristotle University of Thessaloniki for the academic year 2022-2023 |
|
2022–2027 |
MSc "Neuroscience, Neurolinguistics and Applications" |
|
2021–2024 |
|
|
2018–2021 |
Multicenter, double-blind, parallel-group, randomized, controlled study to investigate the efficacy and safety of orally administered Bl 425 809 during 12 weeks treatment period compared to placebo in patients with cognitive impairment due to Alzheimer's Disease. |
|
2018–2027 |
MSc. Clinical Psychology and Neuropsychology |
|
2016–2017 |
Adaptation of the Cognistat screening measure into Greek |
|
2014–2015 |
Collection and electronic input of existing and new cases of patients with Alzheimer's disease |
|
2013–2014 |
Adaptation of multiple Sclerosis Neuropsychological Screening Questionnaire (MSNQ) for the GreeK population |
|
2013–2024 |
Multicenter randomized double placebo-controlled study of parallel variable duration of treatment groups to evaluate the efficacy & safety of siponimid (BAF312) in secondary progressive multiple sclerosis patients |
|
2012–2013 |
Τhe development of self-regulation skills in elementaryschool children and relations with school achievement and performance in attention tasks |
|
2010–2017 |
A single arm,open-label,multicenter study evaluating the long-term safety and tolerability of 0.5mg fingolimod (FTY720) administeres orally once daily in patients with multiple sclerosis |
